IL248169A0 - il-15 group conjugates and polymer - Google Patents
il-15 group conjugates and polymerInfo
- Publication number
- IL248169A0 IL248169A0 IL248169A IL24816916A IL248169A0 IL 248169 A0 IL248169 A0 IL 248169A0 IL 248169 A IL248169 A IL 248169A IL 24816916 A IL24816916 A IL 24816916A IL 248169 A0 IL248169 A0 IL 248169A0
- Authority
- IL
- Israel
- Prior art keywords
- conjugates
- moiety
- polymer
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461974914P | 2014-04-03 | 2014-04-03 | |
| PCT/US2015/023871 WO2015153753A2 (en) | 2014-04-03 | 2015-04-01 | Conjugates of an il-15 moiety and a polymer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL248169A0 true IL248169A0 (en) | 2016-11-30 |
Family
ID=54241432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL248169A IL248169A0 (en) | 2014-04-03 | 2016-10-02 | il-15 group conjugates and polymer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20170035898A1 (enExample) |
| EP (2) | EP3139947B8 (enExample) |
| JP (2) | JP6728055B2 (enExample) |
| KR (1) | KR102432169B1 (enExample) |
| CN (1) | CN106456716A (enExample) |
| AU (3) | AU2015240806B2 (enExample) |
| CA (1) | CA2942571C (enExample) |
| ES (1) | ES2876433T3 (enExample) |
| IL (1) | IL248169A0 (enExample) |
| MA (1) | MA39711A (enExample) |
| MX (2) | MX388865B (enExample) |
| WO (1) | WO2015153753A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105209054A (zh) | 2013-04-18 | 2015-12-30 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素-10治疗疾病和病症的方法 |
| JP2016528879A (ja) | 2013-06-17 | 2016-09-23 | アルモ・バイオサイエンシーズ・インコーポレイテッド | タンパク質の同一性および安定性を評価する方法 |
| HK1226308A1 (zh) | 2013-08-30 | 2017-09-29 | Armo Biosciences, Inc. | 使用白细胞介素-10治疗疾病和病症的方法 |
| US11413332B2 (en) | 2013-11-11 | 2022-08-16 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| US10293043B2 (en) | 2014-06-02 | 2019-05-21 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
| KR20170068553A (ko) | 2014-10-14 | 2017-06-19 | 아르모 바이오사이언시스 인코포레이티드 | 인터류킨-15 조성물 및 이의 용도 |
| JP6675394B2 (ja) | 2014-10-22 | 2020-04-01 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 疾患及び障害の治療のためにインターロイキン−１０を使用する方法 |
| US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
| US20160361415A1 (en) | 2015-05-28 | 2016-12-15 | Armo Biosciences, Inc. | Methods of Using Interleukin-10 for Treating Diseases and Disorders |
| JP7053453B2 (ja) | 2015-08-25 | 2022-04-12 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 疾患及び障害を治療するためのインターロイキン１０の使用方法 |
| MA47290A (fr) | 2015-10-08 | 2019-11-27 | Nektar Therapeutics | Combinaison d'un agoniste sélectif de l'il-2rbeta et d'un agoniste de l'il-15 à action prolongée |
| MX2018007304A (es) * | 2015-12-21 | 2019-03-14 | Armo Biosciences Inc | Composiciones de interleucina-15 y sus usos. |
| US11472856B2 (en) | 2016-06-13 | 2022-10-18 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| CN111093688B (zh) * | 2017-05-15 | 2025-09-16 | 尼克塔治疗公司 | 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法 |
| KR20210032924A (ko) | 2017-09-05 | 2021-03-25 | 토크 테라퓨틱스, 인코포레이티드 | 치료용 단백질 조성물 및 그의 제조 및 사용 방법 |
| WO2019165453A1 (en) | 2018-02-26 | 2019-08-29 | Synthorx, Inc. | Il-15 conjugates and uses thereof |
| AU2019376164B2 (en) * | 2018-11-09 | 2025-10-16 | Nektar Therapeutics | Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent |
| SG11202111175YA (en) * | 2019-04-26 | 2021-11-29 | Prolynx Llc | Slow-release cytokine conjugates |
| US11248025B2 (en) | 2019-06-03 | 2022-02-15 | Medikine, Inc. | IL-2alpha receptor subunit binding compounds |
| PH12022500004A1 (en) * | 2019-08-23 | 2023-04-03 | Synthorx Inc | Il-15 conjugates and uses thereof |
| AU2022249281B2 (en) * | 2021-03-29 | 2025-08-14 | Aj Sciences (Yixing) Co., Ltd | Protein-macromolecule conjugates and methods of use thereof |
| IL309522B2 (en) | 2021-06-23 | 2025-12-01 | Cytune Pharma | Interleukin 15 variants |
| WO2023288226A2 (en) * | 2021-07-12 | 2023-01-19 | Nektar Therapeutics | Polymer engineered forms of interferon-gamma and methods of use |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2025101551A1 (en) * | 2023-11-06 | 2025-05-15 | Regents Of The University Of Minnesota | Prostate-specific membrane antigen (psma)-binding peptides and method of use |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| ATE293168T1 (de) * | 1993-11-12 | 2005-04-15 | Gilead Sciences Inc | Thrombin mutanten |
| PT772624E (pt) | 1994-04-06 | 2001-03-30 | Immunex Corp | Interleucina-15 |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US7008624B1 (en) * | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
| US5795966A (en) * | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| US6362254B2 (en) | 1998-03-12 | 2002-03-26 | Shearwater Corporation | Poly(ethylene glycol) derivatives with proximal reactive groups |
| US6602498B2 (en) | 2000-02-22 | 2003-08-05 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| JP4490290B2 (ja) * | 2002-12-31 | 2010-06-23 | ネクター セラピューティクス アラバマ，コーポレイション | 加水分解安定性マレイミド末端ポリマー |
| AU2004204136B2 (en) | 2003-01-06 | 2008-10-09 | Nektar Therapeutics | Thiol-selective water-soluble polmer derivatives |
| JP2007506789A (ja) * | 2003-09-25 | 2007-03-22 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−２１を用いた自己免疫疾患の治療方法 |
| WO2006017853A2 (en) * | 2004-08-11 | 2006-02-16 | Beth Israel Deaconess Medical Center, Inc. | Mutant interleukin-15-containing compositions and suppression of an immune response |
| JP2008515896A (ja) | 2004-10-05 | 2008-05-15 | オクスナー クリニック ファウンデーション | Ｉｌ−１５によるｂ細胞増殖の増強 |
| US20060257361A1 (en) * | 2005-04-12 | 2006-11-16 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Novel form of interleukin-15, Fc-IL-15, and methods of use |
| PT2279758E (pt) | 2005-06-16 | 2015-05-27 | Nektar Therapeutics | Conjugados possuindo uma ligação degradável e reagentes poliméricos úteis na preparação de tais conjugados |
| CN101686687A (zh) | 2007-02-28 | 2010-03-31 | 塞瑞纳治疗公司 | 活化的聚噁唑啉及包含该聚噁唑啉的组合物 |
| WO2010048184A2 (en) * | 2008-10-21 | 2010-04-29 | Baxter International Inc. | Methods for determining active ingredients in pro-drug peg protein conjugates with releasable peg reagents (in vitro de-pegylation) |
| AU2011282571C1 (en) * | 2010-07-30 | 2018-04-05 | Takeda Pharmaceutical Company Limited | Nucleophilic catalysts for oxime linkage |
| KR102591732B1 (ko) * | 2010-11-12 | 2023-10-19 | 넥타르 테라퓨틱스 | Ｉｌ-2 부분 및 중합체의 접합체 |
| CN102145178B (zh) * | 2011-04-15 | 2012-09-26 | 北京凯因科技股份有限公司 | Peg化白介素15 |
| WO2013020079A2 (en) * | 2011-08-04 | 2013-02-07 | Nektar Therapeutics | Conjugates of an il-11 moiety and a polymer |
-
2015
- 2015-03-31 MA MA039711A patent/MA39711A/fr unknown
- 2015-04-01 WO PCT/US2015/023871 patent/WO2015153753A2/en not_active Ceased
- 2015-04-01 MX MX2016012908A patent/MX388865B/es unknown
- 2015-04-01 EP EP15773976.4A patent/EP3139947B8/en active Active
- 2015-04-01 AU AU2015240806A patent/AU2015240806B2/en active Active
- 2015-04-01 KR KR1020167027127A patent/KR102432169B1/ko active Active
- 2015-04-01 EP EP21169371.8A patent/EP3919071A1/en active Pending
- 2015-04-01 JP JP2016559891A patent/JP6728055B2/ja active Active
- 2015-04-01 ES ES15773976T patent/ES2876433T3/es active Active
- 2015-04-01 US US15/301,681 patent/US20170035898A1/en not_active Abandoned
- 2015-04-01 CN CN201580017361.XA patent/CN106456716A/zh active Pending
- 2015-04-01 CA CA2942571A patent/CA2942571C/en active Active
-
2016
- 2016-09-30 MX MX2021015492A patent/MX2021015492A/es unknown
- 2016-10-02 IL IL248169A patent/IL248169A0/en active IP Right Grant
-
2019
- 2019-12-16 AU AU2019283778A patent/AU2019283778A1/en not_active Abandoned
-
2020
- 2020-04-20 JP JP2020074680A patent/JP2020114875A/ja not_active Withdrawn
-
2021
- 2021-10-28 AU AU2021258008A patent/AU2021258008A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3919071A1 (en) | 2021-12-08 |
| EP3139947B1 (en) | 2021-05-26 |
| MA39711A (fr) | 2015-10-08 |
| AU2015240806A1 (en) | 2016-10-13 |
| EP3139947A4 (en) | 2018-01-17 |
| AU2015240806B2 (en) | 2019-09-19 |
| CN106456716A (zh) | 2017-02-22 |
| AU2021258008A1 (en) | 2021-11-25 |
| US20170035898A1 (en) | 2017-02-09 |
| EP3139947B8 (en) | 2021-06-30 |
| JP2017511322A (ja) | 2017-04-20 |
| AU2019283778A1 (en) | 2020-01-16 |
| EP3139947A2 (en) | 2017-03-15 |
| JP6728055B2 (ja) | 2020-07-22 |
| CA2942571A1 (en) | 2015-10-08 |
| CA2942571C (en) | 2023-09-19 |
| MX388865B (es) | 2025-03-20 |
| ES2876433T3 (es) | 2021-11-12 |
| JP2020114875A (ja) | 2020-07-30 |
| MX2021015492A (es) | 2022-02-22 |
| WO2015153753A3 (en) | 2015-11-26 |
| KR102432169B1 (ko) | 2022-08-11 |
| MX2016012908A (es) | 2017-01-11 |
| WO2015153753A2 (en) | 2015-10-08 |
| KR20170005793A (ko) | 2017-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3139947A4 (en) | Conjugates of an il-15 moiety and a polymer | |
| GB2513048B (en) | Device proximity | |
| ZA201704297B (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| PT3119885T (pt) | Conjugados anticorpo-fynomer | |
| EP3183262A4 (en) | Novel glycan conjugates and use thereof | |
| IL252618A0 (en) | Biomolecular couplings | |
| GB2525767B (en) | Speaker device | |
| EP3207128A4 (en) | Butyrylcholinesterase zwitterionic polymer conjugates | |
| EP3094985A4 (en) | Determination of a location of a device | |
| EP3285799A4 (en) | Conjugates of an il-7 moiety and an polymer | |
| SG11201606893WA (en) | An implantable device | |
| EP3158628A4 (en) | Electromagnetic device | |
| EP3192439A4 (en) | Bioinformation measuring device | |
| IL248443B (en) | A device that can be integrated into a skeletal bone | |
| EP3073763A4 (en) | Speaker device | |
| GB201402998D0 (en) | Amplifier device | |
| EP3214854A4 (en) | Speaker device | |
| EP3166335A4 (en) | Speaker device | |
| GB201418068D0 (en) | Polymer | |
| GB201409933D0 (en) | Novel device | |
| IL246349A0 (en) | factor vii conjugates | |
| SG11201704325QA (en) | Micro-cavity-based force sensor | |
| EP3110513A4 (en) | Willow workout device | |
| GB201420946D0 (en) | Flexible device incorporating microperforators | |
| EP3214853A4 (en) | Speaker device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |